Press Releases

TAINAN, Taiwan, Dec. 5, 2008 (GLOBE NEWSWIRE) -- Himax Technologies, Inc. ("Himax" or "Company") (Nasdaq: HIMX) today announced that fourth-quarter results will be lower than the company's previous guidance given on November 4, 2008, as customers reduce orders amid the slowing worldwide economy.

The Company expects fourth quarter 2008 revenues to decline by 46%-49% from the $230.1 million posted in the third quarter of 2008. Previous guidance provided on November 4 forecasted revenues to decline by 23-28% quarter over quarter.

Gross margin is expected to decline by 3-4 percentage points from the 24.5% posted in the third quarter of 2008. The Company had previously guided for gross margin to decline by 2-3 percentage points sequentially. The Company now expects fourth quarter EPS to be in the range of $0.02-0.04, down from the previous guidance of $0.06-0.08.

Jordan Wu, President and Chief Executive Officer of Himax, commented, "Over the past few weeks, we've seen dramatic reduction in customer orders primary as a result of the extreme slowing of the worldwide economy. Facing the unprecedented industry downturn, we have taken immediate cost-saving measures during the quarter. We expect fourth quarter operating expenses, on both GAAP and Non-GAAP basis, to be significantly lower than the third quarter 2008. With no debts, our balance sheet remains strong and we are confident that we will continue to generate positive operating cash flow in the fourth quarter. Though the short-term visibility is quite limited, we remain focused on investing in R&D and improving our operating efficiency. We will continue to execute the $50 million share buy-back program announced on November 14, 2008."

About Himax Technologies, Inc.

Himax Technologies, Inc. designs, develops, and markets semiconductors that are critical components of flat panel displays. The Company's principal products are display drivers for large-sized TFT-LCD panels, which are used in desktop monitors, notebook computers and televisions, and display drivers for small- and medium-sized TFT-LCD panels, which are used in mobile handsets and consumer electronics products such as digital cameras, mobile gaming devices and car navigation displays. In addition, the Company is expanding its product offering to include LCD TV chipset solution, power management ICs and LCOS microdisplays. Based in Tainan, Taiwan, the Company has regional offices in Hsinchu and Taipei, Taiwan; Ninbo, Foshan, Suzhou and Shenzhen, China; Yokohama, Japan; Anyangsi Kyungkido, South Korea; and Irvine California, USA.

Forward-Looking Statements:

Certain statements in this press release, including statements regarding expected future financial results and industry growth, are forward-looking statements that involve a number of risks and uncertainties that could cause actual events or results to differ materially from those described in this press release. Factors that could cause actual results to differ include, but not limited to, general business and economic conditions and the state of the semiconductor industry; level of competition; demand for end-use applications products; reliance on a small group of principal customers; continued success in technological innovations; development of alternative flat panel display technologies; ability to develop and protect our intellectual property; pricing pressures including declines in average selling prices; changes in customer order patterns; shortages in supply of key components; changes in environmental laws and regulations; exchange rate fluctuations; regulatory approvals for further investments in our subsidiaries; and other risks described from time to time in the Company's SEC filings, including those risks identified in the section entitled "Risk Factors" in its Form 20-F for the year ended December 31, 2007 filed with SEC on June 20, 2008, as amended. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

CONTACT: Himax Technologies, Inc.
         Max Chan, Chief Financial Officer
           +886-2-2370-3999 Ext. 22300
           max_chan@himax.com.tw
         Jessie Wang, Investor Relations
           +886-2-2370-3999 Ext. 22618
           jessie_wang@himax.com.tw

         In the U.S.
         The Ruth Group
         Joseph Villalta
         +1-646-536-7003
         jvillalta@theruthgroup.com

HARBIN, China, Dec. 5 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical took part in an insightful interview in today's issue of The China Perspective.

As a well-known pharmaceutical company in China, China Sky One was honored to receive an interview from The China Perspective, a leading source of China business news, research and analysis that provides insight into the trends, companies and industries that are shaping the Chinese economy. During the interview, Mr. Yan-Qing Liu spoke about the Company's recent acquisitions, its R&D capability and the impact of global financial crisis on pharmaceutical producers. For more information, please visit The China Perspective's website ( http://www.thechinaperspective.com ).

"This is an exciting time in the evolution of the pharmaceutical industry in China, and China Sky One is well positioned to offer insight as a leading drug manufacturer and distributor in China," commented Mr. Yan-Qing Liu, Chairman, CEO and President of China Sky One Medical. "We are thrilled to work with The China Perspective and to share our reflections about the global economic crisis and our expertise in the Chinese pharmaceutical market with the investment community."

About China Sky One Medical, Inc.

China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company (''TDR''), Harbin First Bio- Engineering Company Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Company Pharmaceutical Company ("Jin Chuang") the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .

Safe Harbor Statement

Certain of the statements made in the press release constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.

    For more information, please contact:

    Company Contact:
     China Sky One Medical, Inc.
     Mr. Yubo Hao, CFO
     Tel:   +86-451-5399-4069
     Email: china_sky_one@yahoo.cn

    Investor Relations Contact:
     CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915
     Email: crocker.coulson@ccgir.com
     Web site: http://www.ccgirasia.com

SOURCE China Sky One Medical, Inc.

World's oldest motion picture technology used to demonstrate the world's newest motion technology - Motionflow 240Hz

MILAN, Italy, Dec. 5 /PRNewswire/ -- Sony today announced its first worldwide creative campaign for Sony BRAVIA(R) televisions. The company built the BRAVIA-drome, the centerpiece for Sony's latest marketing campaign, to provide customers with a visual demonstration of Sony's Motionflow technology.

The BRAVIA-drome was inspired by the zoetrope, a device invented in the 19th century to create short 'films' from a series of static images. This modern day zoetrope is 10 meters across, spins at over 40 kph and is the optimal medium for demonstrating how Motionflow 240Hz technology clearly displays today's fast-action motion pictures.

Sony selected soccer for its continuous movement to fully demonstrate the clarity of Motionflow 240Hz for customers. The technology effortlessly eliminates jerkiness and smoothes the flight of the ball as it hits the net, making fans that are watching the game within the comfort of their own homes feel as though they are at the stadium.

The commercial is filming in a square in Venaria, near Turin, and stars FIFA World Player of the Year and Ballon d'Or holder, Brazilian soccer sensation Kaka. The FIFA World Cup winner will appear in a series of images inside the BRAVIA-drome performing some of his legendary skills. To add to the excitement, soccer juggling champion Dan Magness will make an appearance at the shoot as he attempts to smash three Guinness World Records. Magness, already known for breaking several different soccer records, has trained some of the very best players in the world - from Francesco Totti to Michael Owen - in the art of controlling a soccer ball.

The Fallon London advertising agency - the creative team behind the 'Balls,' 'Paint' and 'Play-doh' trilogy of BRAVIA commercials - is producing the commercial which is being directed by up and coming director Vernie Yeung, known for directing music videos for top artists including Kylie Minogue. The commercial will be filmed using Sony's F35 Professional HD camera.

"The BRAVIA-drome has been designed to explain the technology behind Motionflow in a way that makes it easy for anyone to understand," says Giles Morrison, General Manager, Marketing Communications, Sony Europe. "As we have proved with previous campaigns, including 'Balls,' 'Paint' and 'Play-doh,' simple ideas effectively executed can be immensely powerful. This is about delivering a truly spectacular experience that people can believe in. The choice of Kaka was an easy one, as not only does he have that superstar quality but football is an ideal way to show our customers the full effect of Motionflow 240Hz."

"I want to create an air of anticipation amongst the watching TV audience," says director Vernie Yeung. "This is achieved by initially revealing some of the smaller details of the structure, then showing it in its entirety to demonstrate the sheer size and scale of the BRAVIA-drome and finally giving the viewer a glimpse of its surroundings. The suspense builds until the perfectly smooth images of Kaka showcasing his amazing skills are unveiled. This advert is a unique event, demonstrated by the look of sheer awe and amazement on the faces of the watching public."

The BRAVIA-drome - designed for easy dismantling and transport for use beyond the shoot itself - will also appear in print, digital and below-the-line elements, such as store fixtures, point-of-sale items and brochures of the overall campaign. Sony has also designed a range of content exclusively for bloggers, Websites and social networks to provide them with a unique BRAVIA-drome experience. Press release and images are available at www.sony.com/news.

BRAVIA-drome Statistics

    --  The optimum speed of the BRAVIA-drome is 44kph
    --  The BRAVIA-drome can reach speeds of over 50kph
    --  The BRAVIA-drome measures 10m in diameter
    --  It takes 10 men three days to fully assemble the BRAVIA-drome
    --  The BRAVIA-drome is transported by two 40-foot trucks
    --  It took six weeks for the BRAVIA-drome to be built in full for the first
        time
    --  Weighing in at ten tons, it is believed to be the biggest zoetrope ever
        built.  Guinness World Records are attending the shoot to verify this
        record attempt

About Sony:

Sony manufactures audio, video, communications and information technology products for the global consumer and professional markets. With its music, pictures, game and online businesses, Sony is uniquely positioned to be one of the world's leading digital entertainment brands. Sony recorded consolidated global annual sales of EUR 55.83 billion (yen 8,296 billion) for the fiscal year ended March 31, 2007, based on an average market exchange rate for the same period of yen 148.6 to the EUR. It employs approximately 163,000 people worldwide.

In Europe, the Sony Group recorded consolidated annual sales of EUR 13.71 billion (yen 2,038 billion) for the fiscal year ended March 31, 2007. Sony Europe, headquartered at the Sony Center am Potsdamer Platz in Berlin, is responsible for the company's European electronics business and registered consolidated sales of EUR 9.12 billion for the same period.

For more information on Sony Europe, please visit http://www.sony-europe.com and http://www.sony-europe.com/presscenter. For Sony Electronics in the United States, visit www.sony.com/news.

SOURCE Sony

STOCKHOLM, Sweden--(BUSINESS WIRE)-- Academic entrepreneurs from Northern Ireland, Italy, the Netherlands, England, Scotland, and Sweden were named as the winners of the inaugural ACES, the Academic Enterprise Awards 2008, at a ceremony in Stockholm, Sweden.

The prizes awarded by the Science|Business Innovation Board, a blue-ribbon panel of leaders in industry, academia and policy at a ceremony at Sweden's Royal Academy of Engineering, go to companies tackling major issues of health, the environment and security and leaders of technology transfer.

The winners are:

Chemistry/Materials - Andrew Lynn, Orthomimetics Ltd, a spin-out from the Cambridge-MIT Institute, UK, that has developed implants that can be accurately delivered using minimally invasive, single-step procedures.

Life Sciences - Neville H. McClenaghan, Peter R Flatt and Finbarr P.M. O'Harte, Diabetica Ltd, a Northern Ireland spin-out from the University of Ulster's Diabetes Research Group that is developing therapeutics, diagnostics and other technologies to treat Type II diabetes, obesity and metabolic syndrome.

ICT - Pasquale Pigazzini, Augusto Sarti and Stefano Tubaro, Kee Square, a spin-out from the Politecnico di Milano, Italy, that is developing security products that combine high-end image and audio analysis and processing techniques with classification techniques.

Energy/Environment - Adel Sharif, Surrey Acquatechnology Ltd/Modern Water Plc, UK. Sharif's company, a spin-out from the University of Surrey, is developing water purification and desalination technologies.

Fast Start - Gandert Van Raemdonck, Hjalmar Van Raemdonck, Ephicas BV. The company, a spin-out from TU Delft, the Netherlands, Ephicas is developing and producing aerodynamic devices for lorry trailers that reduce fuel consumption up to 15%, saving fuel costs and reducing pollution.

The evening culminated with the announcement of The Bridge Award, for an individual who has done the most to promote policies for entrepreneurship in university or public research institutions. Three outstanding individuals shared the prize.

Tom Hockaday from Isis Innovation, University of Oxford, UK.

Eleanor Taylor from Scottish Enterprise, Scotland, UK.

Hans Wigzell from Karolinska Institutet, Sweden

The ACES programme began in discussions at ESADE Business School in Barcelona and University College London, UK, and was launched in June 2008 at INSEAD, the international business school in Fontainebleau, France, and is supported by a further 24 outstanding European academic institutions. The programme is sponsored by Microsoft Corp., Procter & Gamble, Vinnova, Amgen, Johnson & Johnson Pharmaceutical R&D, CEFIC, IVA-Royal Swedish Academy of Engineering, the Wellcome Trust and WilmerHale. Media partners were MIT Technology Review, the Wall Street Journal Europe and ScanBalt.

    Source: Science|Business

TAMPA, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- UTEK Corporation (NYSE Alternext US: UTK) (LSE-AIM: UTK), a leading innovation services company, and Panel Intelligence, LLC, an independent primary market research leader in the life sciences, have announced an Alliance with UTEK's Pharmalicensing division. The Alliance will enable users of the Pharmalicensing.com online service to purchase market research and due diligence services from Panel Intelligence.

Will Febbo, Chief Executive Officer at Panel Intelligence said, "We believe the Alliance will provide a great benefit to Pharmalicensing's clients by delivering relevant data to accelerate their business development activities. Panel Intelligence's expertise in providing customized healthcare research services is collaborative, thorough and therapeutically driven to bring the best medical experts to focus on a topic."

Mark McBride, Director of Pharmalicensing commented, "We are all delighted to have entered into this Alliance, offering our users access to the unique due diligence services powered by Panel Intelligence. We look forward to working closely with Panel Intelligence to provide these services to our users to further their partnering and licensing activities."

About Panel Intelligence, LLC

Panel Intelligence, LLC, based in Cambridge, Mass., provides primary market research to corporate and financial clients in the Healthcare and CleanTech industries. Our seasoned research staff understands the unique complexities of each industry as well as the types of decisions our clients need to support. As a fully committed and capable research partner, Panel Intelligence works closely with clients to identify objectives, recruit experts, elicit information, and synthesize results. Its domain expertise, global network of experts, and proven online methods all combine to help clients make better decisions. Panel Intelligence, LLC is a wholly owned subsidiary of Merriman Curhan Ford (NASDAQ: MERR). For more information about Panel Intelligence, please visit its website at www.panelintelligence.com.

About Pharmalicensing, Ltd.

Pharmalicensing is the premier biopharmaceutical open innovation resource designed for life science professionals involved with partnering, licensing and business development worldwide. Actively supporting in- and out-licensing activities, Pharmalicensing currently provides partnering services to over 200 client companies around the world. Pharmalicensing is a division of UTEK Corporation. For more information about Pharmalicensing, please visit its website at www.pharmalicensing.com.

About UTEK Corporation

UTEK(R) is a leading innovation services company. UTEK's services enable clients to become stronger innovators, rapidly source externally developed technologies, create value from their intellectual property and gain foresight into marketplace and technology developments that affect their business. UTEK is a business development company. For more information about UTEK, please visit its website at www.utekcorp.com.

Forward-Looking Statements

Certain matters discussed in this press release are "forward-looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words such as UTEK or Panel Intelligence "expects," "should," "believes," "anticipates" or words of similar import. Similarly, statements that describe UTEK's or Panel Intelligence's future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of UTEK or Panel Intelligence and the valuation of UTEK's investment portfolio, which could cause actual results to differ materially from those currently anticipated. Although UTEK and Panel Intelligence believe the expectations reflected in any forward-looking statements are based on reasonable assumptions, it cannot give any assurance that its expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed below. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and UTEK or Panel Intelligence do not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

UTEK's operating results could fluctuate significantly due to a number of factors. These factors include the small number of transactions that are completed each quarter, the value of individual transactions, the timing of the recognition and the magnitude of unrealized and realized gains and losses of companies in its portfolio, UTEK's dependence on the performance of its operating divisions as well as the companies in its portfolio, the possibility that advances in technology could render the technologies it has transferred obsolete, the loss of technology licenses by companies in its portfolio, the degree to which it encounters competition in its markets, the volatility of the stock market and the volatility of the valuations of the companies it has invested in as it relates to its realized and unrealized gains and losses, the concentration of investments in a small number of companies, marketplace demand for innovation consulting services as well as other general economic conditions. As a result of these and other factors, current results may not be indicative of UTEK's future performance. For more information on UTEK and for a more complete discussion of the risks pertaining to an investment in UTEK, please refer to UTEK's filings with the Securities and Exchange Commission.

    Source: UTEK Corporation